Biopharmaceutical Company
S. Con. Res 8 -- Concurrent Resolution on the Budget For Fiscal Year 2014
H Con Res 25 -- Establishing the budget for the US Government for FY 2014 and setting forth appropriate budgetary levels for FY 15 through 2033
HR 933 -- Consolidated and Further Continuing Appropriations Act, 2013
In all of the above the specific issues included potential Medicare offsets that might be applied to prescription drugs Implementation of the "GAIN" provisions/Title VIII of the Food and Drug Administration Safety and Innovation Act (FDASIA) - PL - 112-144;  antibiotic product development incentive and limited population antibiotic product (LPAD) legislation; pharmaceutical trace and trace legislation; and S.  622 - Animal Drug and Animal Generic Drug User Fee Reauthorization Act of 2013 (specifically in regards to potential antibiotic-related provisions) Health care reform implementation; the 340B program of the Health Resources and Services Administration (HRSA), specifically 340B drug pricing program issues, including program expansion and specific issues include HRSA oversight, definition of patient, the ACA's expansion of covered 340B entities S. Con. Res 8 -- Concurrent Resolution on the Budget For Fiscal Year 2014
H Con Res 25 -- Establishing the budget for the US Government for FY 2014 and setting forth appropriate budgetary levels for FY 15 through 2033
HR 933 -- Consolidated and Further Continuing Appropriations Act, 2013
In all of the above the specific issues included potential Medicare offsets that might be applied to prescription drugs
MMM - Medicare/Medicaid PHA - Pharmacy HCR - Health Issues BUD - Budget/Appropriations
2 - HOUSE OF REPRESENTATIVES 1 - SENATE 2 - HOUSE OF REPRESENTATIVES 1 - SENATE 2 - HOUSE OF REPRESENTATIVES 1 - SENATE 2 - HOUSE OF REPRESENTATIVES 1 - SENATE
SLC HEALTH STRATEGIES, LLC
9710 Traville Gateway Drive, Number 157, Rockville, MD, 20850, US
SHARON COHEN SHARON COHEN SHARON COHEN SHARON COHEN